Maravai LifeSciences(MRVI) - 2023 Q2 - Earnings Call Presentation

Financial Performance - Q2 2023 revenue was $69 million[56] - Adjusted EBITDA for Q2 2023 was $9.1 million, with an Adjusted EBITDA Margin of 13%[56] - The company has $580 million in cash and $536 million in long-term gross debt[17, 37] - Adjusted Free Cash Flow was -$18 million in Q2 2023[58] Segment Performance - Nucleic Acid Production revenue was $53 million, representing 77% of total revenue, with $14 million in Adjusted EBITDA; CleanCap® from COVID-19 contributed $11.6 million[60] - Biologics Safety Testing revenue was $16 million, representing 23% of total revenue, with $10 million in Adjusted EBITDA[40, 61] Guidance Update - Updated 2023 revenue guidance is $300 to $325 million, a decrease of $108 million from prior guidance[74] - CleanCap® COVID-19 revenue guidance is $65 million, a decrease of $35 million from prior guidance[74] - Updated Adjusted EPS guidance is $0.04 to $0.08 per share, a decrease of $0.24 per share from prior guidance[74] - Updated Adjusted EBITDA guidance is $70 to $80 million, a decrease of $90 million from prior guidance[74] Strategic Initiatives - Trey Martin has taken over as Maravai's next CEO [9] - The company executed three new license and supply agreements in 1H 2023[16]